Related Experiment Videos
[Neoadjuvant therapy of prostate carcinoma]
1Urologische Klinik, Heinrich-Heine-Universität, Düsseldorf.
Praxis
|February 7, 1998
Summary
Neoadjuvant endocrine therapy can reduce prostate size and lower PSA levels before surgery. While it decreases positive surgical margins in some cases, its long-term survival benefits require further study.
Area of Science:
- Urology
- Oncology
- Endocrinology
Context:
- Preoperative endocrine therapy aims to improve radical prostatectomy outcomes.
- Four prospective, randomized phase-II studies evaluated neoadjuvant antiandrogenic treatment versus no hormonal therapy.
Purpose:
- To assess the efficacy of neoadjuvant antiandrogenic therapy in improving surgical resection and patient outcomes for prostate cancer.
Summary:
- Neoadjuvant antiandrogenic treatment resulted in reduced prostate volume and lower PSA levels.
- A decreased rate of positive surgical margins was observed in cT2-tumors.
- No significant reduction in seminal vesicle or lymph node involvement was noted.
Impact:
- Encouraging pathologic downstaging in T2-tumors suggests potential benefits.
- Long-term follow-up is crucial to determine the impact on disease-free and overall survival.
- Potential disadvantages include cost, side effects, and delayed treatment for hormone-insensitive clones.